These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 22969249)

  • 1. Suppressive effect of 19-nor-1α-25-dihydroxyvitamin D2 on gastric cancer cells and peritoneal metastasis model.
    Park MR; Lee JH; Park MS; Hwang JE; Shim HJ; Cho SH; Chung IJ; Bae WK
    J Korean Med Sci; 2012 Sep; 27(9):1037-43. PubMed ID: 22969249
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antitumor effects of two less-calcemic vitamin D analogs (Paricalcitol and QW-1624F2-2) in squamous cell carcinoma cells.
    Alagbala AA; Johnson CS; Trump DL; Posner GH; Foster BA
    Oncology; 2006; 70(6):483-92. PubMed ID: 17237623
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Vitamin D2 analog 19-nor-1,25-dihydroxyvitamin D2: antitumor activity against leukemia, myeloma, and colon cancer cells.
    Kumagai T; O'Kelly J; Said JW; Koeffler HP
    J Natl Cancer Inst; 2003 Jun; 95(12):896-905. PubMed ID: 12813173
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Paricalcitol, a vitamin d receptor activator, inhibits tumor formation in a murine model of uterine fibroids.
    Halder SK; Sharan C; Al-Hendy O; Al-Hendy A
    Reprod Sci; 2014 Sep; 21(9):1108-19. PubMed ID: 24925855
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 19-nor-1 alpha,25-dihydroxyvitamin D2 (paricalcitol) inhibits the proliferation of human pancreatic cancer cells in vitro and in vivo.
    Schwartz GG; Eads D; Naczki C; Northrup S; Chen T; Koumenis C
    Cancer Biol Ther; 2008 Mar; 7(3):430-6. PubMed ID: 18094617
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 19-nor-1alpha,25-dihydroxyvitamin D(2) (paricalcitol): effects on clonal proliferation, differentiation, and apoptosis in human leukemic cell lines.
    Molnár I; Kute T; Willingham MC; Powell BL; Dodge WH; Schwartz GG
    J Cancer Res Clin Oncol; 2003 Jan; 129(1):35-42. PubMed ID: 12618899
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 1,25-Dihydroxyvitamin D
    Li M; Li L; Zhang L; Hu W; Shen J; Xiao Z; Wu X; Chan FL; Cho CH
    Life Sci; 2017 Jun; 179():88-97. PubMed ID: 28465245
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 19-Nor-1alpha,25-dihydroxyvitamin D2 (paricalcitol) exerts anticancer activity against HL-60 cells in vitro at clinically achievable concentrations.
    Molnár I; Kute T; Willingham MC; Schwartz GG
    J Steroid Biochem Mol Biol; 2004 May; 89-90(1-5):539-43. PubMed ID: 15225834
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effects of 1alpha,24(S)-dihydroxyvitamin D(2) analog on cancer cell proliferation and cytokine expression.
    Shany S; Levy Y; Lahav-Cohen M
    Steroids; 2001; 66(3-5):319-25. PubMed ID: 11179740
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antiproliferative Activity of Double Point Modified Analogs of 1,25-Dihydroxyvitamin D₂ Against Human Malignant Melanoma Cell Lines.
    Piotrowska A; Wierzbicka J; Nadkarni S; Brown G; Kutner A; Żmijewski MA
    Int J Mol Sci; 2016 Jan; 17(1):. PubMed ID: 26760999
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Paricalcitol attenuates renal interstitial fibrosis in obstructive nephropathy.
    Tan X; Li Y; Liu Y
    J Am Soc Nephrol; 2006 Dec; 17(12):3382-93. PubMed ID: 17082242
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oral paricalcitol (19-nor-1,25-dihydroxyvitamin D2) in women receiving chemotherapy for metastatic breast cancer: a feasibility trial.
    Lawrence JA; Akman SA; Melin SA; Case LD; Schwartz GG
    Cancer Biol Ther; 2013 Jun; 14(6):476-80. PubMed ID: 23760489
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of the vitamin D analogues paricalcitol and calcitriol on bone mineral in vitro.
    Balint E; Marshall CF; Sprague SM
    Am J Kidney Dis; 2000 Oct; 36(4):789-96. PubMed ID: 11007682
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Docetaxel-loaded thermoresponsive conjugated linoleic acid-incorporated poloxamer hydrogel for the suppression of peritoneal metastasis of gastric cancer.
    Bae WK; Park MS; Lee JH; Hwang JE; Shim HJ; Cho SH; Kim DE; Ko HM; Cho CS; Park IK; Chung IJ
    Biomaterials; 2013 Jan; 34(4):1433-41. PubMed ID: 23174142
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inecalcitol, an analog of 1,25D3, displays enhanced antitumor activity through the induction of apoptosis in a squamous cell carcinoma model system.
    Ma Y; Yu WD; Hidalgo AA; Luo W; Delansorne R; Johnson CS; Trump DL
    Cell Cycle; 2013 Mar; 12(5):743-52. PubMed ID: 23388458
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Paricalcitol (19-nor-1,25-dihydroxyvitamin D2) and calcitriol (1,25-dihydroxyvitamin D3) exert potent immunomodulatory effects on dendritic cells and inhibit induction of antigen-specific T cells.
    Sochorová K; Budinský V; Rozková D; Tobiasová Z; Dusilová-Sulková S; Spísek R; Bartůnková J
    Clin Immunol; 2009 Oct; 133(1):69-77. PubMed ID: 19660988
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 22-Oxa-1alpha,25-dihydroxyvitamin D3 inhibits metastasis and angiogenesis in lung cancer.
    Nakagawa K; Sasaki Y; Kato S; Kubodera N; Okano T
    Carcinogenesis; 2005 Jun; 26(6):1044-54. PubMed ID: 15718253
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase I/II study of 19-nor-1alpha-25-dihydroxyvitamin D2 (paricalcitol) in advanced, androgen-insensitive prostate cancer.
    Schwartz GG; Hall MC; Stindt D; Patton S; Lovato J; Torti FM
    Clin Cancer Res; 2005 Dec; 11(24 Pt 1):8680-5. PubMed ID: 16361554
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Peritoneal metastasis inhibition by linoleic acid with activation of PPARgamma in human gastrointestinal cancer cells.
    Sasaki T; Fujii K; Yoshida K; Shimura H; Sasahira T; Ohmori H; Kuniyasu H
    Virchows Arch; 2006 Apr; 448(4):422-7. PubMed ID: 16362414
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Possible involvement of RUNX3 silencing in the peritoneal metastases of gastric cancers.
    Sakakura C; Hasegawa K; Miyagawa K; Nakashima S; Yoshikawa T; Kin S; Nakase Y; Yazumi S; Yamagishi H; Okanoue T; Chiba T; Hagiwara A
    Clin Cancer Res; 2005 Sep; 11(18):6479-88. PubMed ID: 16166423
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.